143664-11-3 | Elacridar

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$28.00	$19.00
5mg	95%	in stock	$55.00	$38.00
10mg	95%	in stock	$92.00	$64.00
25mg	95%	in stock	$146.00	$103.00
50mg	95%	in stock	$212.00	$148.00
100mg	95%	in stock	$293.00	$205.00
250mg	95%	in stock	$463.00	$324.00
1g	95%	in stock	$1,084.00	$759.00
5g	95%	in stock	$3,089.00	$2,162.00

Description

• Catalog Number: AE98408
• Chemical Name: Elacridar
• CAS Number: 143664-11-3
• Molecular Formula: C34H33N3O5
• Molecular Weight: 563.6429
• MDL Number: MFCD00912604
• SMILES: COc1cc2CN(CCc3ccc(cc3)NC(=O)c3cccc4c3[nH]c3c(OC)cccc3c4=O)CCc2cc1OC

Computed Properties

• Complexity: 925
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 42
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 8
• XLogP3: 5.6

Literature

• Multiple drug transporters mediate the placental transport of sulpiride.

  Archives of toxicology 20171201

• Abcb1a but not Abcg2 played a predominant role in limiting the brain distribution of Huperzine A in mice.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20170901

• Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20150501

• Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).

  Toxicological sciences : an official journal of the Society of Toxicology 20131201

• Modular construction of quaternary hemiaminal-based inhibitor candidates and their in cellulo assessment with HIV-1 protease.

  Bioorganic & medicinal chemistry 20130901

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp.

  PloS one 20130101

• Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.

  Molecular pharmaceutics 20121105

• Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.

  Molecular cancer therapeutics 20121001

• Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats.

  Pharmaceutical research 20120701

• Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.

  Journal of medicinal chemistry 20120524

• Exploiting transport activity of p-glycoprotein at the blood-brain barrier for the development of peripheral cannabinoid type 1 receptor antagonists.

  Molecular pharmaceutics 20120507

• Stereoselective interaction of pantoprazole with ABCG2. I. Drug accumulation in rat milk.

  Drug metabolism and disposition: the biological fate of chemicals 20120501

• Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux.

  Toxicology and applied pharmacology 20120501

• Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity.

  Journal of medicinal chemistry 20120412

• Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein.

  Journal of medicinal chemistry 20120412

• Understanding the interplay of drug transporters involved in the disposition of rosuvastatin in the isolated perfused rat liver using a physiologically-based pharmacokinetic model.

  Xenobiotica; the fate of foreign compounds in biological systems 20120401

• P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.

  The Journal of pharmacology and experimental therapeutics 20120401

• Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates.

  Drug metabolism and disposition: the biological fate of chemicals 20120401

• Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.

  International journal of cancer 20120101

• A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.

  European journal of nuclear medicine and molecular imaging 20120101

• ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.

  Journal of Alzheimer's disease : JAD 20120101

• Dual approach utilizing self microemulsifying technique and novel P-gp inhibitor for effective delivery of taxanes.

  Journal of microencapsulation 20120101

• The influence of modulation of P-glycoprotein and /or cytochrome P450 3A on the pharmacokinetics and pharmacodynamics of orally administered morphine in dogs.

  Journal of veterinary pharmacology and therapeutics 20111001

• Impact of passive permeability and gut efflux transport on the oral bioavailability of novel series of piperidine-based renin inhibitors in rodents.

  Bioorganic & medicinal chemistry letters 20110915

• Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography.

  Nuclear medicine and biology 20110701

• Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2).

  Bioorganic & medicinal chemistry letters 20110615

• Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).

  The Journal of pharmacology and experimental therapeutics 20110501

• The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux.

  Drug metabolism and disposition: the biological fate of chemicals 20110301

• Synthesis and in vivo evaluation of ¹⁸F-fluoroethyl GF120918 and XR9576 as positron emission tomography probes for assessing the function of drug efflux transporters.

  Bioorganic & medicinal chemistry 20110115

• Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/multidrug resistance 1.

  Drug metabolism and pharmacokinetics 20110101

• Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.

  Molecular cancer 20110101

• P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.

  Drug metabolism letters 20101201

• The transport of gastrodin in Caco-2 cells and uptake in Bcap37 and Bcap37/MDR1 cells.

  Yao xue xue bao = Acta pharmaceutica Sinica 20101201

• In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats.

  Drug metabolism and disposition: the biological fate of chemicals 20101001

• Hepatobiliary disposition of 3alpha,6alpha,7alpha,12alpha-tetrahydroxy-cholanoyl taurine: a substrate for multiple canalicular transporters.

  Drug metabolism and disposition: the biological fate of chemicals 20101001

• Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.

  Drug metabolism and disposition: the biological fate of chemicals 20100901

• In situ intestinal perfusion in knockout mice demonstrates inhibition of intestinal p-glycoprotein by ritonavir causing increased darunavir absorption.

  Drug metabolism and disposition: the biological fate of chemicals 20100901

• Examination of the ability of the nasal administration route to confer a brain exposure advantage for three chemical inhibitors of P-glycoprotein.

  Journal of pharmaceutical sciences 20100701

• Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.

  The Journal of pharmacology and experimental therapeutics 20100701

• Toxicokinetics of the food-toxin IQ in human placental perfusion is not affected by ABCG2 or xenobiotic metabolism.

  Placenta 20100701

• Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.

  European journal of nuclear medicine and molecular imaging 20100501

• Absorption barriers in the rat intestinal mucosa: 2. Application of physiologically based mathematical models to quantify mechanisms of drug permeation and metabolism.

  Journal of pharmaceutical sciences 20100201

• Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier.

  Drug metabolism and disposition: the biological fate of chemicals 20100101

• Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).

  Bioorganic & medicinal chemistry letters 20100101

• The P-glycoprotein inhibitor GF120918 modulates Ca2+-dependent processes and lipid metabolism in Toxoplasma gondii.

  PloS one 20100101

• Hepatitis C virus NS3 protease inhibitors: large, flexible molecules of peptide origin show satisfactory permeability across Caco-2 cells.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20091208

• Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies.

  Journal of pharmaceutical sciences 20091101

• Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers.

  Journal of pharmaceutical sciences 20091101

• Decreased urinary secretion of belotecan in folic acid-induced acute renal failure rats due to down-regulation of Oat1 and Bcrp.

  Xenobiotica; the fate of foreign compounds in biological systems 20091001

• Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine.

  Drug metabolism and disposition: the biological fate of chemicals 20091001

• P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.

  The Journal of pharmacology and experimental therapeutics 20090901

• Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs.

  Pharmaceutical research 20090801

• Identification of the efflux transporter of the fluoroquinolone antibiotic ciprofloxacin in murine macrophages: studies with ciprofloxacin-resistant cells.

  Antimicrobial agents and chemotherapy 20090601

• Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090401

• In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib.

  Nuclear medicine and biology 20090401

• Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design.

  Drug metabolism and disposition: the biological fate of chemicals 20090301

• Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.

  Journal of medicinal chemistry 20090226

• The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.

  Investigational new drugs 20090201

• Development and characterisation of a new model of rat trophoblasts.

  Toxicology in vitro : an international journal published in association with BIBRA 20090201

• Cross-functioning between the extraneuronal monoamine transporter and multidrug resistance protein 1 in the uptake of adrenaline and export of 5-(glutathion-S-yl)adrenaline in rat cardiomyocytes.

  Chemical research in toxicology 20090101

• Knocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretion.

  Molecular pharmaceutics 20090101

• Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells.

  Current eye research 20090101

• 2-[(3-Methoxyphenylethyl)phenoxy]-based ABCB1 inhibitors: effect of different basic side-chains on their biological properties.

  Journal of medicinal chemistry 20081211

• N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) as a chemical ATP-binding cassette transporter family G member 2 (Abcg2) knockout model to study nitrofurantoin transfer into milk.

  Drug metabolism and disposition: the biological fate of chemicals 20081201

• Apparent differences in mechanisms of harmol sulfate biliary excretion in mice and rats.

  Drug metabolism and disposition: the biological fate of chemicals 20081101

• A novel human multidrug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport.

  The Journal of pharmacology and experimental therapeutics 20081101

• Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse.

  Drug metabolism and disposition: the biological fate of chemicals 20080801

• Mechanisms underlying saturable intestinal absorption of metformin.

  Drug metabolism and disposition: the biological fate of chemicals 20080801

• Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).

  Journal of medicinal chemistry 20080612

• Role of P-glycoprotein and the intestine in the excretion of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide] in rodents.

  Drug metabolism and disposition: the biological fate of chemicals 20080601

• Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.

  Journal of cancer research and clinical oncology 20080501

• Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines.

  Basic & clinical pharmacology & toxicology 20080401

• 4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators.

  Bioorganic & medicinal chemistry 20080401

• Synthesis and biological evaluation of (hetero)arylmethyloxy- and arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents.

  Journal of medicinal chemistry 20080313

• Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells.

  Drug metabolism and disposition: the biological fate of chemicals 20080201

• P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.

  Drug metabolism and disposition: the biological fate of chemicals 20080201

• Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice.

  Drug metabolism and disposition: the biological fate of chemicals 20080101

• Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives.

  Bioorganic & medicinal chemistry 20080101

• P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.

  Drug metabolism and disposition: the biological fate of chemicals 20071101

• Placental transfer of quetiapine in relation to P-glycoprotein activity.

  Journal of psychopharmacology (Oxford, England) 20070901

• Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar.

  Pharmaceutical research 20070901

• Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.

  Journal of neurochemistry 20070901

• Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine.

  Drug metabolism and disposition: the biological fate of chemicals 20070701

• Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG.

  British journal of pharmacology 20070701

• Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux.

  British journal of pharmacology 20070701

• A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070601

• The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2).

  British journal of pharmacology 20070501

• Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2.

  Bioorganic & medicinal chemistry 20070415

• Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells.

  Cancer chemotherapy and pharmacology 20070201

• Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters.

  British journal of pharmacology 20070201

• The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.

  Molecular pharmacology 20070101

• Proteomic analysis to dissect mitoxantrone resistance-associated proteins in a squamous lung carcinoma.

  Anticancer research 20070101

• An in vitro and in silico study on the flavonoid-mediated modulation of the transport of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) through Caco-2 monolayers.

  Toxicology and applied pharmacology 20061201

• Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition.

  Journal of medicinal chemistry 20061102

• Expression and transport activity of breast cancer resistance protein (Bcrp/Abcg2) in dually perfused rat placenta and HRP-1 cell line.

  The Journal of pharmacology and experimental therapeutics 20061001

• Role of human placental efflux transporter P-glycoprotein in the transfer of buprenorphine, levo-alpha-acetylmethadol, and paclitaxel.

  American journal of perinatology 20061001

• The complexity of intestinal absorption and exsorption of digoxin in rats.

  International journal of pharmaceutics 20060928

• Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein.

  Drug metabolism and disposition: the biological fate of chemicals 20060701

• Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier.

  The Journal of pharmacology and experimental therapeutics 20060601

• Comparison of drug efflux transport kinetics in various blood-brain barrier models.

  Drug metabolism and disposition: the biological fate of chemicals 20060601

• Saturable absorptive transport of the hydrophilic organic cation ranitidine in Caco-2 cells: role of pH-dependent organic cation uptake system and P-glycoprotein.

  Pharmaceutical research 20060601

• Intestinal absorptive transport of the hydrophilic cation ranitidine: a kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in Caco-2 cells.

  Pharmaceutical research 20060601

• In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.

  Drug metabolism and disposition: the biological fate of chemicals 20060501

• Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20060201

• Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.

  Clinical and experimental pharmacology & physiology 20060101

• Role of P-glycoprotein in the hepatic metabolism of tacrolimus.

  Xenobiotica; the fate of foreign compounds in biological systems 20060101

• The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant Km.

  Pharmaceutical research 20051001

• A combined cell based approach to identify P-glycoprotein substrates and inhibitors in a single assay.

  International journal of pharmaceutics 20050914

• Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1.

  Drug metabolism and disposition: the biological fate of chemicals 20050801

• Functional role of P-glycoprotein in the human blood-placental barrier.

  Clinical pharmacology and therapeutics 20050801

• The impact of pharmacologic and genetic knockout of P-glycoprotein on nelfinavir levels in the brain and other tissues in mice.

  Journal of pharmaceutical sciences 20050601

• Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2.

  Cancer research 20050601

• Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells.

  Drug metabolism and disposition: the biological fate of chemicals 20050501

• The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.

  Cancer research 20050401

• P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice.

  The Journal of pharmacology and experimental therapeutics 20050301

• Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A.

  Molecular pharmacology 20050301

• Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.

  Drug metabolism and disposition: the biological fate of chemicals 20050301

• Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.

  The Journal of pharmacology and experimental therapeutics 20050101

• Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems.

  The Journal of pharmacology and experimental therapeutics 20041201

• Substrates and inhibitors of efflux proteins interfere with the MTT assay in cells and may lead to underestimation of drug toxicity.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20041001

• Quantitative analysis of the P-glycoprotein inhibitor Elacridar (GF120918) in human and dog plasma using liquid chromatography with tandem mass spectrometric detection.

  Journal of mass spectrometry : JMS 20041001

• Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey.

  The Journal of pharmacology and experimental therapeutics 20040801

• Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice.

  Investigational new drugs 20040801

• Differentiation of gut and hepatic first pass metabolism and secretion of saquinavir in ported rabbits.

  The Journal of pharmacology and experimental therapeutics 20040701

• The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.

  Drug metabolism and disposition: the biological fate of chemicals 20040701

• P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro.

  Pharmaceutical research 20040701

• Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein.

  European journal of cancer (Oxford, England : 1990) 20040501

• Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice.

  British journal of pharmacology 20040401

• Flavonoid permeability across an in situ model of the blood-brain barrier.

  Free radical biology & medicine 20040301

• Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells.

  Molecular pharmaceutics 20040112

• Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A.

  International journal of cancer 20031210

• Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918.

  Drug metabolism and disposition: the biological fate of chemicals 20031101

• Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030701

• Effect of efflux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans.

  Drug metabolism and disposition: the biological fate of chemicals 20030301

• Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.

  The Journal of pharmacology and experimental therapeutics 20030201

• A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus.

  The Journal of antimicrobial chemotherapy 20030101

• Evaluation of the permeation characteristics of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs across the blood-brain barrier using an in situ perfused rat brain model.

  The Journal of pharmacology and experimental therapeutics 20021101

• MDR1 modulators improve the chemotherapy response of human hepatoblastoma to doxorubicin in vitro.

  Journal of pediatric surgery 20021101

• Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.

  British journal of cancer 20020909

• Boosting bioavailability of topotecan: what do we gain?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020701

• Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020701

• Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats.

  Drug metabolism and disposition: the biological fate of chemicals 20020501

• A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance.

  Cancer research 20020415

• Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).

  Drug metabolism and disposition: the biological fate of chemicals 20020401

• Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.

  The Journal of pharmacology and experimental therapeutics 20020301

• Anti-secretory properties of non-peptide somatostatin receptor agonists in isolated rat colon: luminal activity and possible interaction with P-glycoprotein.

  British journal of pharmacology 20020301

• Modulation of the multidrug-resistance phenotype by new tropane alkaloid aromatic esters from Erythroxylum pervillei.

  Journal of natural products 20011201

• Bioanalysis and preliminary pharmacokinetics of the acridonecarboxamide derivative GF120918 in plasma of mice and humans by ion-pairing reversed-phase high-performance liquid chromatography with fluorescence detection.

  Journal of chromatography. B, Biomedical sciences and applications 20010805

• Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010401

• Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice.

  Pharmaceutical research 20010201

• In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.

  Cancer research 20010115

• Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines.

  Bioorganic & medicinal chemistry letters 20010108

• Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.

  British journal of cancer 20010101